Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) that has shown efficacy with acceptable tolerability in two Phase 3 clinical trials in adult patients with CKD associated with type 2 diabetes (T2D) and more recently in a Phase 3 trial involving patients with heart failure (HF) with mildly reduced or preserved ejection fraction. The gene discussed is NR3C2; the disease is type 2 diabetes mellitus.